Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications

Abstract Alterations of mitogen-activated protein kinase kinase 1 (MEK1) are commonly associated with tumorigenesis, and MEK1 is thought to be a suitable targeted therapy for various cancers. However, abnormal MEK1 alterations and their relevant clinical implications are unknown. Our research compre...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhiyang Zhou, Bi Peng, Juanni Li, Kewa Gao, Yuan Cai, Zhijie Xu, Yuanliang Yan
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b9595cdb825245dc94645c30ef9b2c5e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b9595cdb825245dc94645c30ef9b2c5e
record_format	dspace
spelling	oai:doaj.org-article:b9595cdb825245dc94645c30ef9b2c5e2021-12-02T18:50:52ZIntegrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications10.1038/s41598-021-97840-02045-2322https://doaj.org/article/b9595cdb825245dc94645c30ef9b2c5e2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-97840-0https://doaj.org/toc/2045-2322Abstract Alterations of mitogen-activated protein kinase kinase 1 (MEK1) are commonly associated with tumorigenesis, and MEK1 is thought to be a suitable targeted therapy for various cancers. However, abnormal MEK1 alterations and their relevant clinical implications are unknown. Our research comprehensively analyzed the MEK1 alteration spectrum and provided novel insight for targeted therapies. There were 7694 samples covering 32 types of cancer from The Cancer Genome Atlas (TCGA) database. They were used to conduct an integrative analysis of MEK1 expression, alterations, functional impacts and clinical significance. There was a dramatic difference in the alteration frequency and distribution and clinical implications in 32 types of cancer from the TCGA. Skin cutaneous melanoma (SKCM) has the most alterations and has therapeutic targets located in the protein kinase domain, and the growing expression of SKCM is positively related to patient prognosis. MEK1 expression in lung adenocarcinoma (LUAD), kidney renal papillary cell carcinoma (KIRP), esophageal carcinoma (ESCA) and liver hepatocellular carcinoma (LIHC) is decreased, which is associated with better prognosis, while MEK1 expression in thymoma (THYM), stomach adenocarcinoma (STAD), kidney renal clear cell carcinoma (KIRC), testicular germ cell tumors (TGCTs) and head and neck squamous cell carcinoma (HNSC) is increased, which is associated with better prognosis. Mesothelioma (MESO) has the second highest alterations but has no therapy targets. This study provided a great and detailed interpretation of MEK1 expression, alterations and clinical implications in 32 types of cancer and reminded us to fill the gap in MEK1 research from a new perspective.Zhiyang ZhouBi PengJuanni LiKewa GaoYuan CaiZhijie XuYuanliang YanNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Zhiyang Zhou Bi Peng Juanni Li Kewa Gao Yuan Cai Zhijie Xu Yuanliang Yan Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications
description	Abstract Alterations of mitogen-activated protein kinase kinase 1 (MEK1) are commonly associated with tumorigenesis, and MEK1 is thought to be a suitable targeted therapy for various cancers. However, abnormal MEK1 alterations and their relevant clinical implications are unknown. Our research comprehensively analyzed the MEK1 alteration spectrum and provided novel insight for targeted therapies. There were 7694 samples covering 32 types of cancer from The Cancer Genome Atlas (TCGA) database. They were used to conduct an integrative analysis of MEK1 expression, alterations, functional impacts and clinical significance. There was a dramatic difference in the alteration frequency and distribution and clinical implications in 32 types of cancer from the TCGA. Skin cutaneous melanoma (SKCM) has the most alterations and has therapeutic targets located in the protein kinase domain, and the growing expression of SKCM is positively related to patient prognosis. MEK1 expression in lung adenocarcinoma (LUAD), kidney renal papillary cell carcinoma (KIRP), esophageal carcinoma (ESCA) and liver hepatocellular carcinoma (LIHC) is decreased, which is associated with better prognosis, while MEK1 expression in thymoma (THYM), stomach adenocarcinoma (STAD), kidney renal clear cell carcinoma (KIRC), testicular germ cell tumors (TGCTs) and head and neck squamous cell carcinoma (HNSC) is increased, which is associated with better prognosis. Mesothelioma (MESO) has the second highest alterations but has no therapy targets. This study provided a great and detailed interpretation of MEK1 expression, alterations and clinical implications in 32 types of cancer and reminded us to fill the gap in MEK1 research from a new perspective.
format	article
author	Zhiyang Zhou Bi Peng Juanni Li Kewa Gao Yuan Cai Zhijie Xu Yuanliang Yan
author_facet	Zhiyang Zhou Bi Peng Juanni Li Kewa Gao Yuan Cai Zhijie Xu Yuanliang Yan
author_sort	Zhiyang Zhou
title	Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications
title_short	Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications
title_full	Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications
title_fullStr	Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications
title_full_unstemmed	Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications
title_sort	integrative pan-cancer analysis of mek1 aberrations and the potential clinical implications
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/b9595cdb825245dc94645c30ef9b2c5e
work_keys_str_mv	AT zhiyangzhou integrativepancanceranalysisofmek1aberrationsandthepotentialclinicalimplications AT bipeng integrativepancanceranalysisofmek1aberrationsandthepotentialclinicalimplications AT juannili integrativepancanceranalysisofmek1aberrationsandthepotentialclinicalimplications AT kewagao integrativepancanceranalysisofmek1aberrationsandthepotentialclinicalimplications AT yuancai integrativepancanceranalysisofmek1aberrationsandthepotentialclinicalimplications AT zhijiexu integrativepancanceranalysisofmek1aberrationsandthepotentialclinicalimplications AT yuanliangyan integrativepancanceranalysisofmek1aberrationsandthepotentialclinicalimplications
_version_	1718377528049008640

Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications

Ejemplares similares